Aggrastat (tirofiban HCI)
Board of Directors
Medicure Focuses On
The high-dose bolus (HDB) dosing regimen has been added to the Aggrastat (tirofiban HCI) Prescribing Information.
medicure is traded
on TSX Venture (MPH)
The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban HCI).
Signup for our emails
News Releases and Investment Information
Aggrastat® is Medicure's leading speciality pharmaceutical product.
April 27, 2015
Medicure Q1 Results and Conference Call Dates
April 23, 2015
Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT
April 22, 2015
Medicure to Present at the 2015 Bloom Burton & Co. Healthcare Conference